ILF3 and hepatocellular carcinoma: Interleukin enhancer-binding factor 3 (IlF3) antisense RNA 1 (ILF3-AS1) promotes HCC cell proliferation, migration, and invasion increases ILF3 m6A levels in an m6A-dependent manner via METTL3, and is an important oncogene in HCC progression, providing a new therapeutic target for HCC (Bo et al., 2021).